

## Parkinson's disease guideline committee meeting

**Date:** 14 & 15 July 2016

**Location:** NICE offices, Manchester

**Minutes:** Final

<b>Committee members present</b>	
Paul Cooper (Chair)	Present for all
Janine Barnes (JB)	Present from item 2 day 1
Ivan Bennett (IB)	Present for day 1
Alistair Church (AC)	Present from item 2 day 1
Debbie Davies (DD)	Present from item 2 day 1
Richard Grunewald (RG)	Present for all
Graham Lennox (GL)	Present for all
Fiona Lindop (FL)	Present for all
Jane Little (JL)	Present for all
Lynne Osbourne (LO)	Present for all
Paul Shotbolt (PS)	Present from item 2 day 1
Matthew Sullivan (MS)	Present for all
Beverly Sheaf (BS) (co-opted)	Present for day 2
Nicholas Miller (NM) (co-opted)	Present for day 2
Julian Evans (JE) (co-opted)	Present for item 2 – 3 day 2
Clare Johnson (CJ) (co-opted)	Present for day 2

<b>In Attendance:</b>		
Sue Spiers (SS)	Associate Director	Present for all
Gabriel Rogers (GR)	Health Economist	Present for all
Joshua Pink (JP)	Technical Advisor	Present for all
Aimely Lee (AL)	Technical Analyst	Present for all
Daniel Davies (DaD)	Project Manager	Present for all
Louise Picton (LP)	Senior Medicines Adviser	Present for all
Ben Doak (BD)	NICE Commissioning Manager	Present for all
Sarah Palombella	Editor	Present for all

**Observers:**

### 4.0.3 DOC Cmte minutes

None
------

<b>Committee member apologies:</b>
------------------------------------

Richard Walker (RW)
---------------------

Robin Fackrell (RF)
---------------------

<b>Thursday 14 July 2016</b>
------------------------------

<b>1. Welcome, introductions, minutes, Dol and matters arising</b>
--

The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts. No new declarations were made.
---

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.
---

The committee reviewed the minutes of the previous meeting and agreed they were an accurate record of the discussions.
--

<b>2. Review Question 19: What is the comparative effectiveness of pharmacological interventions as adjuvants to levodopa preparations?</b>
---

AL presented the evidence for the review question
---

The committee considered the evidence presented and drafted three recommendations
---

<b>3. Chapter introductions</b>
---------------------------------

PC requested volunteers from the committee for assistance in writing introductions for chapters in the full guideline.
--

All chapters received volunteers, and DD advised that he would contact these following the meeting with further details.
--

<b>4. Consultation process</b>
--------------------------------

DD provided a brief presentation on the process and dates followed during the consultation process
--

<b>5. Review Research Recommendations</b>
---

The committee reviewed the research recommendations made in the guideline, and noted their top 5 most recommendations for research.
---

#### 4.0.3 DOC Cmte minutes

<b>6. Review re-run evidence searches &amp; recommendations</b>
---

AL presented the re-run evidence searches for the review questions.
---

The committee reviewed their recommendations in light of the updated evidence.
--

<b>5. AOB</b>
---------------

PC reminded attendees of the 09.30 start for the second day.
--

There was no other business raised
------------------------------------

<b>Friday 15 July 2016</b>
----------------------------

<b>1. Welcome, introductions, minutes, DoI and matters arising</b>
--

The Chair asked those present to declare any new conflicts of interest relevant to the areas being discussed or potential new conflicts. No new declarations were made.
---

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.
---

<b>2. Review of DBS/ Duodopa chapter</b>
--

GR presented HE evidence on the DBS/ duodopa chapter.
---

The committee considered this evidence, but made no changes to the recommendations.
---

<b>3 &amp; 4. Review re-run evidence searches &amp; recommendations</b>
---

AL continued the evidence re-run presentation from day 1.
---

The committee reviewed their recommendations in light of the updated evidence.
--

<b>5. AOB</b>
---------------

PC reiterated the consultation deadlines to the committee, and thanked them for their work.
---